Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWRBiotechnology
+$4.49 today
- Market cap
- $6.09B
- Beta
- 1.27
- P/E (TTM)
- -38.4
- EPS (TTM)
- -$2.11
Volume 2.42M
Average 1.82M
ARWR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR
Revenue · Q4 FY2026 · quarter ended Sep 2026
Revenue declines year over year
Q4 FY2026 revenue of $37.79M fell 85.3% year over year, behind the -45.6% change in trailing-twelve-month revenue. Sequentially, it fell 49.8% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $306.26M (-32.1%) for the fiscal year ending Sep 2027, a step up from the -45.6% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $37.79M-49.8% QoQ
- Last fiscal yearSep 2026
- $450.82M-45.6% YoY
- LTMSep 2026
- $450.82M-45.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -85.3% | -83.9% | +1.4 pp |
| 1 year | -45.6% | -32.1% | +13.6 pp |
| 3-year CAGR | +23.3% | +30.2% | +7.0 pp |
| 5-year CAGR | +44.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2026
- 450.82M USD
- Year-over-year change
- -45.6%
- 4-year CAGR
- +16.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 450.82M | -45.6% |
| FY2025 | 2025-09-30 | 829.45M | +23258.2% |
| FY2024 | 2024-09-30 | 3.55M | -98.5% |
| FY2023 | 2023-09-30 | 240.74M | -1.0% |
| FY2022 | 2022-09-30 | 243.23M | — |
Revenue vs competitors
How ARWR compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -45.6% is the 5th highest of 6, against a peer median of -29.2%.
- Over three fiscal years its annual growth of +23.3% compares with a peer median of +35.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $4.8B USD | +95.1% | +53.0% | |
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Sep 2026 | $450.82M USD | -45.6% | +23.3% | |
| LTM Mar 2026 | $71.8M USD | -31.6% | +127.1% | |
| LTM Mar 2026 | $45.35M USD | -66.4% | -31.1% | |
| LTM Mar 2026 | €13.44M EUR | -29.2% | +62.0% | |
| LTM Mar 2026 | $921.49K USD | — | -68.4% | |
| Peer median (excluding ARWR) | — | -29.2% | +35.1% | |
Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 243.23M | 240.74M | 3.55M | 829.45M | 450.82M |
| Cost of Revenue | 10.42M | 12.49M | 18.6M | 0 | 1.8M |
| Gross Profit | 232.81M | 228.24M | (15.04M) | 829.45M | 449.02M |
| Gross Margin | 95.7% | 94.8% | -423.7% | 100.0% | 99.6% |
| Research & Development | 288.5M | 342.31M | 489.22M | 607.16M | 739.14M |
| Selling, General & Admin | 124.43M | 90.93M | 96.82M | 121.92M | 202.05M |
| Operating Expenses | 411.32M | 433.24M | 586.04M | 731.1M | 1.16B |
| Depreciation & Amortization | 10.42M | 12.49M | 18.6M | 23.93M | 26.62M |
| EBITDA | (162.29M) | (175.67M) | (561.51M) | 164.82M | (603.59M) |
| EBITDA Margin | -66.7% | -73.0% | -15812.8% | 19.9% | -133.9% |
| Operating Income | (178.51M) | (205M) | (601.08M) | 98.35M | (707.17M) |
| Operating Margin | -73.4% | -85.2% | -16927.1% | 11.9% | -156.9% |
| Interest Income | 5.03M | 15.3M | 22.72M | 37.29M | 57.86M |
| Interest Expense | 0 | 18.33M | 32.35M | 89.36M | 93.71M |
| Other Income / Expenses | 5.8M | (1.49M) | (11.38M) | (46.81M) | (16.74M) |
| Income Before Tax | (172.71M) | (206.49M) | (612.46M) | 51.53M | (723.92M) |
| Pre-Tax Margin | -71.0% | -85.8% | -17247.5% | 6.2% | -160.6% |
| Income Tax Expense | 3.79M | 2.78M | (2.77M) | 21.42M | (6.78M) |
| Net Income | (176.06M) | (205.28M) | (599.49M) | (1.63M) | (724.21M) |
| Net Margin | -72.4% | -85.3% | -16882.4% | -0.2% | -160.6% |
| EPS (Basic) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| EPS (Diluted) | (1.67) | (1.92) | (5.00) | (0.01) | (5.11) |
| Weighted Avg Shares | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
| Weighted Avg Shares (Diluted) | 105.43M | 106.75M | 119.78M | 133.76M | 141.63M |
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
Intrinsic Alpha fair value
Locked
Current Price
$43.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.